Publikationer

Ett urval av tillgängliga publikationer med arfolitixorin

”Phase Ib/II study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC)”

Sebastian Stintzing, et al.

”Cytotoxicity of arfolitixorin versus leucovorin (LEU) with 5-fluorouracil (5FU) and oxaliplatin in colorectal cancer (CRC) patient-derived tumoroids (PDTs)”

Peter Eide, et al.

”The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial”

Aldina Pivodic, et al.

”Dose-dependent cytotoxicity of arfolitixorin, a direct-acting folate, versus leucovorin with 5-fluorouracil in patient-derived colorectal cancer tumoroids (PDTs)”

Jarle Bruun, et al.

”Final Analysis of the Greek cohort of the AGENT Phase III study Arfolitixorin in Metastatic Colorectal Cancer”

Anna Koumarianou, et al.

”A Randomized Phase III Study of Arfolitixorin Versus Leucovorin with 5-Fluorouracil, Oxaliplatin and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial”

Josep Tabernero, et al.

”A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer”

Göran Carlsson, et al.

”Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone”

Bengt Glimelius, et al

”MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer”

David A. Drubin, et al.

”Tumoral expression of folate-associated genes is associated with progression-free survival of patients with advanced colorectal cancer”

Yvonne Wettergren, et al.

“Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy”

Roger Tell, et al.

”Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin”

Helena Taflin, et al.

”An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer”

Heinz-Josef Lenz, et al.

”Open-label Phase III Study of Arfolitixorin vs Leucovorin in Modifi ed FOLFOX-6 for First-line Treatment of Metastatic Colorectal Cancer: AGENT”

Sebastian Stintzing, et al.

”ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”.

Göran Carlsson, et al.

”Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”

Bengt Gustavsson, et al.

”Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”

Peter V. Danenberg, et al.

”A review of the evolution of systemic chemotherapy in the management of colorectal cancer”

Bengt Gustavsson, et al.

”A pharmacokinetic and pharmacodynamic investigation of Modufolin^® compared to Isovorin^® after single dose intravenous administration to patients with colon cancer: a randomized study”

Wettergren, et al.

”Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages”

Taflin, Helena, et al.